Eli Lilly's retatrutide, a next-generation weight-loss drug, has passed its first major late-stage trial (Phase 3 trial), which tests whether a drug actually works in patients. This is an important step toward getting the drug approved by regulators.

• •Retatrutide passed its first Phase 3 trial
• •Drug is positioned as Lilly's next-generation obesity therapy
• •Result advances retatrutide toward regulatory submission

Retatrutide, a new weight-loss drug, showed patients lost 28.7% of their body weight in testing. PatentVest says the company's next big challenge will be protecting its patents so competitors can't copy the drug.

• •Retatrutide produced 28.7% body weight loss in testing
• •PatentVest flags IP protection as the next competitive battleground

• •Retatrutide framed as crossing the surgical weight-loss threshold

A partner company has moved a triple agonist peptide (a drug that works on three different receptors to reduce appetite and weight) that was originally developed by Gubra into Phase 2 testing (the second stage of human trials). The drug targets obesity, joining other similar medications in development.

• •Gubra-originated triple agonist obesity peptide advanced to Phase 2 by partner
• •Asset is a triple receptor agonist targeting obesity

Boehringer Ingelheim's retatrutide, a dual-action weight-loss drug, helped people lose up to 16.6% of their body weight in a trial. Retatrutide works on two hormones in the body to reduce hunger and help with obesity.

• •Boehringer Ingelheim's dual agonist drove up to 16.6% body weight loss in a trial
• •The drug acts on two hormones to reduce hunger and treat obesity

• •Independent piece examines safety of retatrutide use among gym-goers
• •Users claim retatrutide is more powerful than Ozempic

• •Lexaria planning 18-arm study comparing pills and capsules across two GLP-1 drugs

• •Retatrutide is described as an unapproved peptide related to Ozempic
• •Mechanism is positioned as different from existing GLP-1 weight-loss drugs

• •GoodRx publishes comparison of retatrutide versus tirzepatide

• •Retatrutide profiled as a newer GLP injection medication

• •Retatrutide profiled as a new GLP injection medication